세계의 수면제 시장 규모 - 유형별, 약물 유형별, 수면장애 유형별 예측(2023-2032년)

Sleep medications market size is predicted to grow at over 6.8% CAGR from 2023 to 2032. The rising stress levels and hectic lifestyles have led to an upsurge in the prevalence of sleep disorders globally. The growing elderly population, increasing incidences of chronic diseases, along with the improved awareness about the importance of sleep routine are fueling the product demand.

Moreover, the adoption of sedentary lifestyles and the high prevalence of mental health disorders have further accelerated the adoption of effective sleep medications, fostering market expansion. According to a large-scale study co-led by researchers at Harvard Medical School and University of Queensland, 50% of the global population will develop at least one mental health disorder by the age of 75 years. As mental health issues develop, the need for sleep medications will also increase in the coming years.

The overall sleep medications market is classified based on type, drug class, sleep disorder type, and region.

The OTC drug segment is expected to observe 7.1% CAGR from 2023 to 2032, primarily due to the ease of accessibility and the growing preference for self-medication among the consumers. With the introduction of several OTC sleep aids that offer quick relief from common sleep disorders, consumers are increasingly inclined towards these medications. The demand for OTC sleep drugs continue to boost, supported by the product innovations and marketing strategies adopted by leading pharmaceutical companies.

The restless legs sleep disorder (RLSD) segment is anticipated to witness nearly 8.4% CAGR during 2023 and 2032. The rising awareness about the ailment among the common population is leading to an increased demand for specific medications catering to this particular condition. The market players are actively engaged in R&D activities to introduce effective formulations. The increasing number of diagnosed cases and the development of novel treatment options focusing on addressing its symptoms will aid the segment growth.

Asia Pacific sleep medication market will observe around 7.9% CAGR from 2023 to 2032 owing to the rapid urbanization, changing lifestyle patterns, and the increasing prevalence of sleep disorders in countries such as China, India, and Japan. The region is witnessing improvement in healthcare infrastructure, which along with the rising awareness about the importance of sleep health is expected to drive the market growth. The pharma companies are strategically focusing on expanding their presence in the Asia Pacific market by launching tailored products and strengthening distribution networks, thereby capitalizing on the growing opportunities in this region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market definition
• 1.2 Base estimates & calculations
• 1.3 Forecast calculation
• 1.4 Covid-19 impact analysis at global level
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Secondary
    • 1.6.1.1 Paid sources
    • 1.6.1.2 Public sources
  • 1.6.2 Primary

Chapter 2 Executive Summary

• 2.1 Sleep medications industry 360 degree synopsis, 2018 - 2032 (USD Million)
  • 2.1.1 Business trends
  • 2.1.2 Regional trends
  • 2.1.3 Type trends
  • 2.1.4 Drug class trends
  • 2.1.5 Sleep disorder type trends

Chapter 3 Sleep Medications Market Insights

• 3.1 Industry landscape, 2018 - 2032 (USD Million)
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of sleep disorders
    • 3.2.1.2 Stressful lifestyles of people
    • 3.2.1.3 Advancements in drug development
    • 3.2.1.4 Growth in aging population across the globe
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side effects associated with sleeping medications
    • 3.2.2.2 Availability of alternative Therapies
    • 3.2.2.3 Limited insurance coverage for sleep medications
• 3.3 Growth potential analysis
  • 3.3.1 By type
  • 3.3.2 By drug class
  • 3.3.3 By sleep disorder type
• 3.4 COVID-19 impact analysis
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

• 4.1 Introduction
• 4.2 Company matrix analysis, 2022
• 4.3 Competitive positioning matrix, 2022
• 4.4 Strategic dashboard, 2022

Chapter 5 Sleep Medications Market, By Type, 2018 - 2032 (USD Million)

• 5.1 Key trends, by type
• 5.2 Prescription-based drugs
• 5.3 OTC drugs

Chapter 6 Sleep Medications Market, By Drug Class, 2018 - 2032 (USD Million)

• 6.1 Key trends, by drug class
• 6.2 Benzodiazepines
• 6.3 Antidepressants
• 6.4 Antihistamines
• 6.5 Sedating antipsychotics
• 6.6 Other drug classes

Chapter 7 Sleep Medications Market, By Sleep Disorder Type, 2018 - 2032 (USD Million)

• 7.1 Key trends, by sleep disorder
• 7.2 Insomnia
• 7.3 Sleep apnea
• 7.4 Restless legs syndrome
• 7.5 Narcolepsy
• 7.6 Sleep walking
• 7.7 Other sleep disorders

Chapter 8 Sleep Medications Market, By Region, 2018 - 2032 (USD Million)

• 8.1 Key trends, by region
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East & Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 Rest of Middle East & Africa

Chapter 9 Company Profiles

• 9.1 Pfizer Inc.
• 9.2 Sanofi SA
• 9.3 Eisai Co., Ltd.
• 9.4 Sunovion Pharmaceuticals Inc.
• 9.5 Merck and Co Inc.
• 9.6 Takeda Pharmaceutical Company Limited
• 9.7 Johnson & Johnson
• 9.8 Novartis AG
• 9.9 Vanda Pharmaceuticals
• 9.10 Teva Pharmaceuticals